channel affinity and selectivity. Whereas the affinity to Kv1.1 and Kv1.3 did not change significantly, the affinity to Kv1.2 and K Ca 3.1 was drastically reduced with the truncations. It is surprising that a striking gain in potency was observed for Kv3.2. In contrast, a truncation of the C-terminal domain, expected to partially disrupt the toxin ␤-sheet structure, resulted in a significant decrease or a complete loss of activity on all channel types tested. These data highlight the value of structurefunction studies on the extended N-terminal domain of [Lys 16 ,Asp 20 ]-OSK1 to identify new analogs with unique pharmacological properties.
K Ca 3.1 was drastically reduced with the truncations. It is surprising that a striking gain in potency was observed for Kv3.2. In contrast, a truncation of the C-terminal domain, expected to partially disrupt the toxin ␤-sheet structure, resulted in a significant decrease or a complete loss of activity on all channel types tested. These data highlight the value of structurefunction studies on the extended N-terminal domain of [Lys 16 , Asp 20 ]-OSK1 to identify new analogs with unique pharmacological properties.
OSK1 is a toxin that originates from the venom of the Asian scorpion Orthochirus scrobiculosus (Jaravine et al., 1997) . It is composed of 38 amino acid residues with three disulfide bridges that are arranged according to a conventional pattern of the type C1-C4, C2-C5, and C3-C6 (Jaravine et al., 1997; Mouhat et al., 2004a,b) . OSK1, also referred to as ␣-KTx3.7, belongs to the ␣-KTx3 family (Tytgat et al., 1999; Rodriguez de la Vega and Possani, 2004) and shares between 74 and 90% sequence identity with other members of this family, such as kaliotoxin 1 (Aiyar et al., 1995) , agitoxins 1, 2, and 3 (Garcia et al., 1994) , and Buthus martensi kaliotoxin-like BmkTX (Romi-Lebrun et al., 1997) . The 3-D solution structure of OSK1, as determined by 1 H NMR (Protein Data Bank accession code 1SCO), indicates that the toxin folds according to the canonical ␣/␤ architectural motif, which corresponds to a helical structure connected to an antiparallel ␤-sheet by two disulfide bridges (Bontems et al., 1991; Jaravine et al., 1997; Mouhat et al., 2004b) . In the case of OSK1, the helical structure is a distorted ␣-helix running from amino acid residues 10 to 21, whereas the antiparallel ␤-sheet is composed of two strands going from residues 24 to 28 and 32 to 38. The N-terminal domain contains an exArticle, publication date, and citation information can be found at http://molpharm.aspetjournals.org. doi:10.1124/mol.105.017210.
ABBREVIATIONS: OSK1, toxin 1 from the scorpion Orthochirus scrobiculosus; AOSK1, [Lys 16 , Asp 20 ]-OSK1; [⌬ 1 ]-AOSK1, AOSK1 deleted of the amino acid residue at position 1; [⌬ 1-4 ]-AOSK1, AOSK1 deleted of the four N-terminal residues; [⌬ [1] [2] [3] [4] [5] [6] ]-AOSK1, AOSK1 deleted of the six N-terminal residues; [⌬ 1-7 ]-AOSK1, AOSK1 deleted of the seven N-terminal residues; [⌬ 36 -38 ]-AOSK1, AOSK1 deleted of the last three C-terminal residues; [⌬ 1 ,Thr 2 ]-AOSK1, AOSK1 deleted of the amino acid residue at position 1 and mutated at position 2 by a threonine residue; Fmoc, N␣-fluoren-9-ylmethyloxycarbonyl; TFA, trifluoroacetic acid; HPLC, high-performance liquid chromatography; Kv, mammalian voltage-gated K ϩ channels (Kv1.1 to Kv1.7); K Ca 2.1 (also referred to as SK1), type-1 small-conductance Ca 2ϩ -activated K ϩ channel; K Ca 2.2 (also referred to as SK2), type 2 small-conductance Ca 2ϩ -activated K ϩ channel; K Ca 3.1 (also referred to as IK1), type 1 intermediate-conductance Ca 2ϩ -activated K ϩ channels; K Ca 1.1 (also referred to as BK), large-conductance Ca 2ϩ -activated K ϩ channel; Kv11.1 (also referred to as HERG), human ether-a-gogo-related Ktended structure (residues 2-6) resembling a third strand of the ␤-sheet.
OSK1 is a potent blocker of Kv1-family potassium channels that targets Kv1.1 (IC 50 ϭ 0.6 nM for current block), Kv1.2 (IC 50 ϭ 5.4 nM), and Kv1.3 (IC 50 ϭ14 pM) with picomolarto-nanomolar affinity. It is also moderately active on the calcium-activated K ϩ channel K Ca 3.1 (IC 50 ϭ 225 nM) (Mouhat et al., 2004b) . Because OSK1 blocks both Kv1.3 and K Ca 3.1, two channels involved in the activation of human T and B cells Wulff et al., 2004) , it constitutes a good lead compound for the development of new, OSK1-derived immunosuppressive peptides of therapeutic value. We have reported the design and chemical production of an OSK1 analog, [Lys 16 , Asp 20 ]-OSK1 (here referred to as AOSK1), that is approximately five times more potent on Kv1.3 (IC 50 ϭ 3 pM) than OSK1 itself (Mouhat et al., 2004b) . As such, AOSK1 is one of the most potent Kv1.3 channel blockers characterized so far. AOSK1 blocks K Ca 3.1 with roughly the same affinity as OSK1 itself, but it displays a higher selectivity over Kv1.1 and Kv1.2. Here, this analog was used as a template for the production and pharmacological characterization of a number of novel OSK1 analogs. Trimming of the N-terminal extended domain of AOSK1 specifically reduced the affinity for Kv1.2 and K Ca 3.1 but did not significantly change the affinity for Kv1.1 and Kv1.3. Partial sequence trimming also proved to be an unexpected and powerful approach to obtain AOSK1 analogs with pharmacological activities toward new K ϩ channel subtypes such as Kv3.2.
Materials and Methods
Materials. Fmoc-L-amino acids, 4-hydroxymethylphenyloxy resin, and reagents used for peptide synthesis were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). Solvents were analytical grade products from SDS (Witham, Essex, UK). L929, B82, and MEL cells stably expressing rat Kv1.2, mouse Kv1.3, human Kv1.5, and mouse Kv3.1 have been described previously (Grissmer et al., 1994 Production of AOSK1 Analogs by Solid-Phase Peptide Synthesis. AOSK1 was obtained as described previously (Mouhat et al., 2004b (1% cross-linked; 0.65 mmol of amino group per gram) using 1 mmol Fmoc-L-amino acid derivatives (Merrifield, 1986) . Side chain-protecting groups for trifunctional residues were trityl for cysteine, asparagine, histidine, and glutamine; t-butyl for serine, threonine, tyrosine, aspartate, and glutamate; 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for arginine; and t-butyloxycarbonyl for lysine. N ␣ -amino groups were deprotected by successively treating with 18 and 20% (v/v) piperidine/N-methylpyrrolidone for 3 and 8 min, respectively. After three washes with N-methylpyrrolidone, the Fmoc-amino acid derivatives were coupled (20 min) as their hydroxybenzotriazole active esters in N-methylpyrrolidone (4-fold excess). After peptides were assembled, and removal of N-terminal Fmoc groups, the peptide resins (approximately 1.5 g) were treated under stirring for 3 h at 25°C with mixtures of TFA/H 2 O/thioanisole/ethanedithiol (73:11:11:5, v/v) in the presence of crystalline phenol (2.1 g) in final volumes of 30 ml per gram of peptide resins. The peptide mixtures were filtered, precipitated, and washed twice with cold diethyloxide. The crude peptides were pelleted by centrifugation (3200g for 8 min). They were then dissolved in H 2 O and freeze-dried. Reduced AOSK1 analogs were solubilized at a concentration of approximately 0.6 mM in 0.2 M Tris-HCl buffer, pH 8.3, for oxidative folding (40-120 h depending on the peptide, 20°C). The folded/oxidized peptides were purified to homogeneity by reverse-phase high-performance liquid chromatography (HPLC) (C 18 Aquapore ODS, 20 m, 250 ϫ 10 mm; PerkinElmer) by means of a 60-min linear gradient of 0.10% (v/v) TFA/H 2 O (buffer A) with 0 to 40% of 0.08% (v/v) TFA/acetonitrile (buffer B) at a flow rate of 6 ml/min ( ϭ 230 nm). The purity and identity of each peptide were assessed by 1) analytical C 18 reverse-phase HPLC (C 18 Lichrospher 5 m, 4 ϫ 200 mm; Merck, Darmstadt, Germany) using a 40-min linear gradient of buffer A with 0 to 60% of buffer B at a flow rate of 1 ml/min; 2) amino acid analysis after peptide acidolysis [6 M HCl/2% (w/v) phenol, 20 h, 120°C, N 2 atmosphere]; and 3) molecular mass determination by matrix-assisted laser-desorption ionization-timeof-flight spectrometry.
Conformational Analyses of AOSK1 Analogs by One-Dimensional 1 H NMR. AOSK1 analogs were dissolved in a 9/1 mixture of H 2 O/D 2 O (v/v) at final concentrations of 50 M. All 1 H NMR measurements were performed on a Bruker DRX 500 spectrometer equipped with an HCN probe (Bruker, Newark, DE), and selfshielded triple axis gradients were used. Experiments were performed at 300 K.
Lethality of AOSK1 Analogs in Mice. The peptides were evaluated for toxicity in vivo by determining the LD 50 value after intracerebroventricular injection into 20-g C57/BL6 mice (approved by the French ethics committee; animal testing agreement number 13.231 delivered by the Direction Départementale des Services Vétérinaires des Bouches-du-Rhône, Préfecture des Bouches-du-Rhône, France). Groups of six to eight mice per dose were injected with 5 l of peptide solution containing 0.1% (w/v) bovine serum albumin and 0.9% (w/v) NaCl.
Cell Cultures and Transfections. B82, MEL, L929, and HEK cells stably expressing the above-mentioned voltage-and Ca 2ϩ -activated K ϩ channels and COS-7 cells used for transfection were maintained in Dulbecco's modified Eagle's medium with Earle's salts (Invitrogen, Carlsbad, CA), and 10% heat-inactivated fetal calf serum (PAA Laboratories GmbH, Linz, Austria) as described previously (Grissmer et al., 1994) . Mouse Kv1.1 in a GFPIre vector (Invitrogen), human Kv1.2 in a pcDNA3/Hygro vector (Invitrogen), and rat Kv3.2 in a pcDNA3 vector (Protinac GmbH, Hamburg, Germany) were transfected into COS-7 cells either alone or with a green fluo- Fig. 1 . Amino acid sequences and chemical syntheses of OSK1, AOSK1, and analogs thereof. a, the amino acid sequences (one-letter code) of OSK1, AOSK1, and AOSK1 analogs were aligned according to the positions of their half-cystine residues (numbered from 1 to 6). The positions of half-cystine residues are highlighted in gray boxes. Mutated residues in AOSK1 (Lys 16 and Asp 20 ) and related analogs are shown in boldface type. The positions of OSK1 secondary structures (an N-terminal extended domain located before the first half-cystine residue, an ␣-helix, and a two-stranded ␤-sheet structure) are indicated by solid lines above the toxin amino acid sequence (1). The 3-D solution structure of OSK1 can be found in the Protein Data Bank (code 1SCO). b, analytical C 18 reverse-phase HPLC elution profiles of folded/oxidized OSK1, AOSK1, and its N-or C-terminal truncated analogs after their purification steps. c, deduced and experimental relative molecular masses (MϩH) ϩ of synthetic OSK1, AOSK1, and its analogs.
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rescent protein-expressing construct using FuGene6 Transfection Reagent (Roche Diagnostics, Mannheim, Germany) according to the recommended protocol. Currents were recorded 1 to 3 days later in green fluorescent protein-positive cells. Electrophysiology. Electrophysiological experiments were carried out at 22 to 24°C using the patch-clamp whole-cell recording mode (Hamill et al., 1981; Rauer and Grissmer, 1996) . Cells were bathed with mammalian Ringer's solution: 160 mM NaCl, 4.5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES, pH 7.4 with NaOH, with an osmolarity of 290 to 320 mOsM. When AOSK1 analogs were applied, 0.1% bovine serum albumin was added to the Ringer's solution. A syringe-driven perfusion device was used to exchange the external recording bath solution. Two internal pipette solutions were used: one for measuring voltage-gated K ϩ currents that contained 155 mM KF, 2 mM MgCl 2 , 10 mM HEPES, and 10 mM EGTA, pH 7.2 with KOH, with an osmolarity of 290 to 320 mOsM; the other was for measuring Ca 2ϩ -activated K ϩ currents that contained 135 mM potassium aspartate, 8.7 mM CaCl 2 , 2 mM MgCl 2 , 10 mM EGTA, and 10 mM HEPES, pH 7.2 with KOH, with an osmolarity of 290 to 320 mOsM. A free [Ca 2ϩ ] i value of 1 M was calculated. All currents through voltage-gated K ϩ channels were elicited by 200-ms depolarizing voltage steps from Ϫ80 to ϩ40 mV. Potassium currents through K Ca 1.1, K Ca 2.1, and K Ca 3.1 were elicited by 1 M internal [Ca 2ϩ ] i and 200-ms voltage ramps from Ϫ120 to ϩ40 mV. Electrodes were pulled from glass capillaries (Science Products, GmbH, Hofheim, Germany) and fire-polished to resistances of 2.5 to 5 M⍀. Membrane currents were measured with an EPC-9 or EPC-10 patch-clamp amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany) interfaced to a computer running acquisition and analysis software (Pulse and PulseFit). When voltage-gated K ϩ currents were measured, the capacitive and leak currents were subtracted using a P/10 procedure. Series resistance compensation (Ͼ80%) was used for currents greater than 2 nA. 
Results
Syntheses of AOSK1 Analogs. A comparison of the amino acid sequences of OSK1, AOSK1, and its analogs is provided in Fig. 1a . AOSK1 is an OSK1 analog with two mutations in positions 16 (acidic Glu 16 replaced by basic lysine) and 20 (basic Lys 20 replaced by acidic aspartic acid). Although the net global charge of AOSK1 is the same as that of OSK1, the distribution of charged amino acid residues is different between the two compounds. A previous study dem- (Mouhat et al., 2004b) . AOSK1 is also more selective for Kv1.3 than OSK1. We therefore used it as a template for the rationale design of new structural analogs in which we trimmed either the N or C terminus. In both cases, the number and relative positioning of all six halfcystine residues forming the three-disulfide bridges were preserved. The standard structural motif for the ␣/␤ scaffold in most scorpion toxins can be described by X n CX n CX 3 CX n -(G/A/S)XCX n CXCX n (where X represents an unspecified amino acid residue and n a variable number of residues). Boldface X n at N-and C-terminal extremities represent the residues that were selectively trimmed in the design of AOSK1 analogs. Using this approach, four N-terminal trun- -6 ]-AOSK1, and [⌬ 1-7 ]-AOSK1) were chemically produced that shortened the N-terminal extended domain but kept the first AOSK1 half-cystine residue intact. We further synthesized an analog in which we truncated the first N-terminal amino acid residue (Gly 1 ) and mutated the second amino acid residue of AOSK1 from Val 2 to threonine ([⌬ 1 ,Thr 2 ]-AOSK1). This point mutation was selected to produce an AOSK1 analog possessing an N-terminal domain (i.e., TIINVK) that is identical with those of margatoxin and noxiustoxin, two scorpion toxins that potently block Kv1.3 Rodriguez de la Vega et al., 2003) . In addition, a C-terminaltruncated AOSK1 analog ([⌬ 36-38 ]-AOSK1) was synthesized to evaluate the importance of this domain. The latter truncates half of the second strand (amino acid sequence 32-38) of the ␤-sheet structure, and we therefore expected it to show a reduced potency because of the reported importance of the ␤-sheet structure for Kv channel blockage (Regaya et al., 2004) . All of the peptides were assembled by solid-phase synthesis using stepwise Fmoc/t-butyl chemistry, as described previously (Merrifield, 1986) . After assembly, crude reduced peptides were obtained in yields ranging from 70 to 80%. The peptides were folded/oxidized under standard alkaline conditions and purified by preparative C 18 reverse-phase HPLC. Homogeneity of the purified peptides was Ͼ99%, as assessed by analytical HPLC (Fig. 1b) . Mass spectrometry analyses of the peptides using the matrix-assisted laserdesorption ionization-time-of-flight technique gave experimental molecular masses similar to the deduced molecular masses (Fig. 1c) , validating the identity of the desired products. All peptides were also characterized and quantified by amino acid analyses after acidolysis. A complete Edman sequencing was performed for some of them to further validate the final products (data not shown). The yield of peptide synthesis ranged between 1 and 5%.
Structural Analysis of AOSK1 and Truncated Analogs by 1 H NMR. One-dimensional 1 H NMR was used to verify that the truncations did not generate unfolded species (Fig. 2) . The well-dispersed signals of the amide regions suggest that the AOSK1 analogs are folded in compact conformations.
Comparison of Lethal Activities between AOSK1 and Its Analogs in Mice. The synthetic peptides were compared for their lethal activities by intracerebroventricular injection in mice (Fig. 3) . All peptides were lethal in mice with characteristic symptoms of K ϩ channel-acting toxins, such as tremor, convulsions, and spasmic paralysis followed by death. The following order of in vivo lethality was observed (from the most to the least potent peptide): [36] [37] [38] ]-AOSK1. The greatest difference in lethality between AOSK1 and [⌬ [1] [2] [3] [4] [5] [6] [7] ]-AOSK1, its N-terminal most truncated analog, is 6-fold. A good correlation seems to exist between the size of the N-terminal truncation of AOSK1 and the ) dramatically reduced toxicity and increased the LD 50 value 16-fold compared with AOSK1. Accordingly, a previous structural characterization of OSK1 (Jaravine et al., 1997) revealed that Thr 36 side chain and Lys 38 main chain mobility are important for the docking of OSK1 to K ϩ channels. Pharmacological Activity of AOSK1 Peptides on a Large Set of K ؉ -Channel Subtypes. The pharmacological profile of AOSK1 analogs was examined on 10 voltage-gated and 3 Ca 2ϩ -activated K ϩ -channel subtypes. None of the newly synthesized peptides (OSK1, AOSK1, and its analogs) showed any activity on either the voltage-gated channels Kv1.4, Kv1.5, Kv1.6, Kv1.7, Kv3.1, and Kv11.1 or the Ca 2ϩ -activated K ϩ channels K Ca 1.1 and K Ca 2.1 at micromolar concentrations. In contrast, the peptides inhibited the Kv-1 family channels Kv1.1, Kv1.2, Kv1.3, the Kv3-family channel Kv3.2 and the intermediate-conductance Ca 2ϩ -activated K ϩ channel K Ca 3.1 with varying potencies (Table 1) . As illustrated in Table 1 and Fig. 4 , [⌬ 36-38 ]-AOSK1 was the least effective of all analogs in blocking K ϩ -channel currents. This result agrees well with the observation that [⌬ 36-38 ]-AOSK1 also shows the lowest activity when injected intracerebroventricular into mice (Fig. 3) . However, [⌬ 36-38 ]-AOSK1 low activity in vitro and in vivo was not unexpected because the integrity of the ␤-sheet structure has been reported to be crucial for the recognition of voltage-gated Kv and Ca 2ϩ -activated K Ca 3.1 potassium channels by scorpion toxins (Castle et al., 2003; Rodriguez de la Vega et al., 2003; Jouirou et al., 2004; Regaya et al., 2004) . In contrast, the most severe truncation of the N-terminal extended region of AOSK1 (i.e., [⌬ 1-7 ]-AOSK1) produced differential effects depending on the subtype of K ϩ channel (Fig. 4) . AOSK1 activities on Kv1.1 and Kv1.3 currents were affected very little by the truncation of the last N-terminal seven residues in [⌬ [1] [2] [3] [4] [5] [6] [7] ]-AOSK1 as shown in the dose-response curves in Fig. 4b . [⌬ 36-38 ]-AOSK1 is shown for comparison. Whereas [⌬ 1-7 ]-AOSK1's potency in blocking Kv1.1 (IC 50 ϭ 7.9 nM) and Kv1.3 (IC 50 ϭ 114 pM) decreased only 20-to 38-fold, it was completely inactive on Kv1.2 currents at 1 M (Fig. 4) , translating into a more than 338-fold loss in activity. Because the truncation of entire N-terminal extended domain of AOSK1 in [⌬ 1-7 ]-AOSK1 showed such a differential effect on the affinity to Kv1.1, Kv1.2, and Kv1.3, we next examined whether milder truncations of this N-terminal domain could preserve the drastic reduction of activity on Kv1.2 while generating analogs with better affinities for Kv1.1 and Kv1.3. Figure 5 shows the effects of a progressive trimming of the N-terminal domain on the IC 50 values of the resulting AOSK1 analogs. The data demonstrate that N-terminal domain trimming reduces the potency of the compounds to block Kv1.2 much more than their potency to block Kv1.1 and Kv1.3. This observation indicates the greater importance of the N-terminal extended domain for Kv1.2 channel recognition by AOSK1. The [⌬ 1 ]-AOSK1 analog was of particular interest because it was 10-and 8-fold less potent on Kv1.2 and Kv1.3 but 2-fold more potent on Kv1.1 than AOSK1.
We further evaluated [⌬ 1 ,Thr 2 ]-AOSK1 because its N-terminal domain is identical with the Kv1.3-blocking scorpion toxins [␣-KTx2.1 (noxiustoxin) and ␣-KTx2.2 (margatoxin)] (Tytgat et al., 1999; Rodriguez de la Vega et al., 2003 (Fig. 4) . Comparison for each peptide between IC 50 values on individual channels and LD 50 values indicates an interesting trend worth discussing. In brief, it seems that the two most important channels for lethality in mouse brain are Kv1.1 and Kv1.2, as noticed previously (Mouhat et al., 2004b) . It also seems that pharmacological activity on Kv3.2 is not essential for lethal potency. A tendency for a greater implication of Kv1.1 over Kv1.2 in the peptide-induced lethal effects is also evidenced. However, it should be noted that lethality probably involves other uncharacterized channels making such comparisons difficult.
Discussion
The scorpion toxin OSK1 serves as a good lead for the design of new Kv1.3 channel blockers because of its potent action on this channel type, with an IC 50 value of 14 pM. OSK1's ability to also block other voltage-gated K ϩ channels such as Kv1.1 and Kv1.2 (in the low nanomolar concentration range) and one Ca 2ϩ -activated K ϩ channel (K Ca 3.1) with moderate activity (at high nanomolar concentration) means that the toxin displays an unusual wide range of channel targets. AOSK1 is an even more interesting lead for further derivatization because it is one of the most potent Kv1.3 channel blockers described so far (Middleton et al., 2003; Mouhat et al., 2004b (Kalman et al., 1998 ) but better than ShK-F6CA (Beeton et al., 2003) or ShK(L5) (Beeton et al., 2005) . In addition, AOSK1 displays an even larger pharmacological profile through its additional action on Kv3.2. Therefore, AOSK1 is, to our knowledge, the second Kv3.2 channel blocker reported hitherto, after the sea anemone toxin ShK acting in the low nanomolar concentration range (Yan et al., 2005) . Here, a strategy of domain trimming was used for the first time to generate new pharmacological profiles.
Several conclusions can be drawn from the experimental data obtained with these AOSK1 analogs. First, trimming in the C-terminal region of AOSK1 is expected to alter its ␤-sheet structure (Jaravine et al., 1997) and thereby reduces activity on all tested target channels. Second, trimming of the N-terminal region seems to be a more attractive strategy because the changes in activity differed greatly from one channel subtype to the other. Indeed, Kv1.1 and Kv1.3 channels were far less susceptible to decreases in analog affinity than was Kv1.2. It is interesting that a limited trimming of the AOSK1 N terminus turned out to be an interesting route for producing analogs with increased activity toward Kv3.2. We surmise that limited truncation may facilitate the access to the binding site of the peptides in the outer vestibule of the channel. As such, this indicates that some toxins can be inactive for a given channel type because of accessibility problems and perhaps not because they do not recognize a binding site on the channel. In future experiments, it will be interesting to combine various experimental strategies to obtain still more powerful toxin-derived drugs acting on specific voltage-gated and Ca 2ϩ -activated potassium channels. In particular, structural determination and docking simulations of truncated AOSK1 peptides on the various target K ϩ channels will be greatly helpful for this purpose. The challenge is to produce more selective AOSK1 analogs with high potencies on the Kv1.3 channel, with or without potent activity on K Ca 3.1 channel. In the end, such structure-function studies on AOSK1 may be useful for the production of potent immunosuppressive drugs. Combining N-terminal truncations with point mutations is clearly a powerful way to create new selective toxin-derived peptide blockers for Kv1.3, Kv1.1, K Ca 3.1, and Kv3.2 channels.
